The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The $280m is a crude estimate of the test value within the $2.8b purchase, no growth and no superior product mark up has been added to Accustem. My view it’s worth around $600/700m at present, once at market gaining contracts maybe over $1b we hope
Whilst the Accustem Shares will be allotted on the completion of the Demerger, it is unlikely that the process to obtain a standard listing on the Official List and admission to trading on the London Stock Exchange will be complete by the date of completion of the Demerger. Accordingly, no Accustem Shares will be actually issued (or CREST accounts credited or Accustem ADSs issued) until the earlier of (i) Accustem Admission; and (ii) 2 months from the date of the completion of the Demerger. This is to prevent the issue of large numbers of physical share certificates which would then need to be replaced or dematerialised upon Accustem Admission.
Before the end of this year
January earliest for stem i thought
Accustem valuation is 280 million dollars. This is the most accurate valuation to date by H.C Wainwright.
Sounds like some think they will be trading STEM Monday but they won't! At that time you will still only be able to trade TILS which will be going north by the week.! Hold them tight and take STEM as a Brucy bonus with bags of potential.
We won’t know til we float that Stem boat on the open sea . goodnight all .
Davey how much do you estimate the market value of Accustem/StemprintER to be?
Steve I find myself agreeing with your high and low on whatever days this week but if you could get in and out at these values Stem would have to open on the markets at over a pound for it to be better to hold than trade surely you don't see the stem initial price being over a quid.
Chat room is quite amusing today, some crash test dummies have entered the building. More fun than the normal sycophantic day in day out TILS love in. Welcome gents.
a £1 delta means the market is attributing a valuation of £191m to Accustem/StemprintER which will not be the case
I’m going for £2.30 close on Thursday and £1.30 close Friday
Possibly get hammered, RNS!
It’s called nominal for a reason and means nothing. TILS share priced will get hammered but it presents a further opportunity to top up and make some profit
joey - your theory is correct if the current mcap of Tiziana attributed a full and fair value to StemprintER, which it doesn't, hence the demerger!
The board of Tils have said all what I said.
Personally I would say Least 2.50. Which would give a mc of half bill , as it has been tried and tested
By experts and just needs the rubber stamp , so to speak.
Joeydiamond absolute tosh.
Joey your not listening, the market had no value for stem in Tils, the whole point of demerger, so no reduction in Tils share price on demerger, especially if RNS is released on news we all know is imminent . Stem will find its own value on float , but I personally would start very high as no money is to be raised yet.
Do the majority of members of this board think that stem will open at a £1 or more?
The question you need to ask is not what the nominal value is but how much is STEM/SPARE worth in the market to a buyer? How much is this asset worth? Do you think the new company is worth £3 million only?
For example if you believe the new company valuation is worth £150 million then it logical to assume TILs market cap will reduce by this much. SP will then be closer to £1.
What we need to find out if what Stems likely valuation to a prospective buyer is, what is the technology worth?
Oh 2p submitted to court , leaves us Tils with 1p. But hey doesn’t mean a thing Share Price has no relation nominal share value , especially when we have so many goodies.
which presumably is for the £3m book cost of stem and the £1m cash transfer?
Theoretically there will be a £4m reduction in the mcap of Tiziana (circa 2p) as that is the official capital reduction amount that has been submitted to the Court.
Cloudy390, agreed and well said